Medicenna Therapeutics Corp. (NASDAQ:MDNA) Q2 2023 Earnings Conference Call November 4, 2022 8:30 AM ET

Company Participants

Dan Ferry - IR, LifeSci Advisors

Fahar Merchant - President & CEO

Liz Williams - CFO

Conference Call Participants

David Martin - Bloom Burton

Catherine Novack - Jones Search

Operator

Hello and welcome to the Medicenna Therapeutics' Fiscal Second Quarter Earnings Call. All participants are in a listen-only mode. There will be a Q&A session at the end of the prepared remarks. Please be advised this call is being recorded at the company's request.

I would now like to turn the call over Dan Ferry of LifeSci Advisors. Please go ahead.

Dan Ferry

Thank you, operator and thank you all for participating in today's conference call. This morning, Medicenna issued a press release providing financial results and corporate updates for the quarter ended September 30th, 2022. If you have not yet seen the press release, it is available on the Investors page of Medicenna’s website.

Before we begin, I would like to remind you that certain statements and information shared during this call, constitute forward-looking information within the meaning of applicable securities laws. All statements other than statements of historical facts shared during this call and that relate to the future operations of the company, and other statements that are not historical facts, including statements related to the clinical potential and development of MDNA11, preliminary clinical data, cash runway, the presentation of additional data, and other milestones are forward-looking statements that are subject to risks and uncertainties. There could be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause actual results to differ materially from the company's expectations, include the risks detailed in the Annual Information Form, Management's Discussion and Analysis, and Form 20-F of the company, and in other filings made by the company with the applicable securities regulators from time-to-time in Canada and the United States.

Listeners are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the company.

You are cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect, and actual results may differ materially from those anticipated.